WAS

WASP actin nucleation promoting factor, the group of Wiskott-Aldrich Syndrome protein family

Basic information

Region (hg38): X:48676596-48691431

Previous symbols: [ "IMD2", "THC" ]

Links

ENSG00000015285NCBI:7454OMIM:300392HGNC:12731Uniprot:P42768AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Wiskott-Aldrich syndrome (Supportive), mode of inheritance: AD
  • thrombocytopenia 1 (Supportive), mode of inheritance: XL
  • X-linked severe congenital neutropenia (Supportive), mode of inheritance: XL
  • Wiskott-Aldrich syndrome (Definitive), mode of inheritance: XL
  • X-linked severe congenital neutropenia (Moderate), mode of inheritance: XL
  • X-linked severe congenital neutropenia (Strong), mode of inheritance: XL
  • Wiskott-Aldrich syndrome (Strong), mode of inheritance: XL
  • X-linked severe congenital neutropenia (Definitive), mode of inheritance: XL
  • Wiskott-Aldrich syndrome (Definitive), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Wiskott-Aldrich syndrome; Thrombocytopenia 1; Neutropenia, severe congenital, X-linkedXLAllergy/Immunology/Infectious; Hematologic; PharmacogenomicProphylaxis and early and aggressive treatments for infections, and avoidance of circumstances that would result in severe bleeding, including certain medications, may be beneficial; HSCT, and genetically modified HSCT (gene therapy) have been describedAllergy/Immunology/Infectious; Dermatologic; Hematologic13133561; 4177931; 4177932; 3995178; 3284030; 1960605; 8279047; 8069912; 7795648; 7537115; 1611094; 7579347; 8682510; 10575547; 8931701; 10447259; 11242115; 11447283; 15142877; 11238097; 11242115; 16804117; 17065640; 17065636; 17250667; 19006568; 18724301; 18479478; 20301357; 21067383; 22052860; 22338148; 22426750; 22456069; 22523910; 23023736; 23237501; 23264593; 23343520; 23498591; 23527602; 23845947; 23943155; 37478401
Individuals can have immune dysfunction, such as in SCNX, which is due to constitutively activating variants

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the WAS gene.

  • Thrombocytopenia 1;Wiskott-Aldrich syndrome;X-linked severe congenital neutropenia (30 variants)
  • not provided (29 variants)
  • X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome (23 variants)
  • Wiskott-Aldrich syndrome (16 variants)
  • Thrombocytopenia 1 (10 variants)
  • X-linked severe congenital neutropenia;Wiskott-Aldrich syndrome;Thrombocytopenia 1 (6 variants)
  • Wiskott-Aldrich syndrome;X-linked severe congenital neutropenia;Thrombocytopenia 1 (5 variants)
  • Thrombocytopenia 1;X-linked severe congenital neutropenia;Wiskott-Aldrich syndrome (5 variants)
  • WAS-related disorder (3 variants)
  • X-linked severe congenital neutropenia (3 variants)
  • Thrombocytopenia (2 variants)
  • Wiskott-Aldrich syndrome;Thrombocytopenia 1;X-linked severe congenital neutropenia (2 variants)
  • Inborn genetic diseases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the WAS gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
133
clinvar
12
clinvar
148
missense
15
clinvar
19
clinvar
124
clinvar
20
clinvar
5
clinvar
183
nonsense
19
clinvar
4
clinvar
1
clinvar
24
start loss
1
clinvar
1
frameshift
44
clinvar
15
clinvar
59
inframe indel
3
clinvar
8
clinvar
1
clinvar
12
splice donor/acceptor (+/-2bp)
9
clinvar
4
clinvar
13
splice region
3
1
14
25
2
45
non coding
1
clinvar
1
clinvar
62
clinvar
9
clinvar
73
Total 89 45 137 215 27

Highest pathogenic variant AF is 0.00000895

Variants in WAS

This is a list of pathogenic ClinVar variants found in the WAS region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-48681722-CAGCAGGTTGGAGGTGCTCCAGGCCCGAAGCTTAGCTGTGAGTGGGGACACGGGAGGGAGGTTGGAACTGCCACTGCAGAAGGGGTTCTGAACCTAGGTTCAGGAGAGAGGCTTTGAACCTGCACGTGTGGGAAGCCATGGAAGTTTCCAGGAAGGACTGCAGGTCCCAACTGGAGATGTGCCGTTCCTCCTTCAGGTACCTGGGAATGTCAGTCACACCCCAGACCTGCTCAGCTCCCCCAAACTGCTGTTCCTGTATCTGAGAGCTTCAAGTCTCCAAATGGCCTACCTCATACATGGGGAAACTGAGGCCTGGGGAGGCCGGGGACTGAGCTAGCATTCACTTGTGGAAATAGTCTGGCATCATCTGGAGAAGTTAGAGACATGCAAACCCTACAGCCCTCAGATTCCCGTCTGAGAGTCTGCATGCCTATGTGGACCAGGAGATGTGTGCGGGAGTGAACACTGCAGTGTTGCTCCCAACAGCAAGAACCAGAAGCAGCCCAAAGGGCTGTTACAGGAGAATATGGACACCCAGGCTGCACATGCACACCATGGAATGCTGTATGGCAGTGGAAATAAATGAACAGCTACCACTATAGGCAAACAGGAATCACAGCAACAGCCAAGAGTGAAGGCGTGGAGGGACGAGACCATGCACTCACACCTGGCCTGCCTGGCTCGCACTCCGGGCAAAGGGGTCAGAACAGTGACTGGCACACACGTTAAGTGCTATGTGAGTGTTAAGATAAAACTAGGATGTCCAGTGGGGAGAAAGCAAGCCTTTGAAGATTATGTGCTTTTACAAACTTCAAGTGCAATGAAAACTAAACAAGATGTTGTTCAGGCATTCATATATGATATAAAGTTCCTTTCTTTAAAAAAGGGATGGGCTGGGCACGGTGGCTCACGCCTGTAATTCTAATACTTTGGGAGGCCGAGGCAGGTGGATCACGAGGTCGAGAAATCGAGACCATCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAAAAATTAGCTGGGCGTGGTGGCGTGTGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAGTCACTTGAACCCGGGAGGCAAAGGTTGCAGTGAGCCGAGATCGTGCCACCGCACTCCAGCCTGGCGACAGAGTGAGACTCCATCTCAAAAAAAAAAAGAAAAAAAAAAGTATGACAAGCAGAAAGTAATTTGGGAGCTGCGGGGAGGCAAGGGTAAGGGATGGGGAAGTGGACCAGAGGCATATGCGTCATTGGCAGTGTCTAAGCACTCACGATAGGCGTGGATCACAGGGGCTCGCTCTGTAATTAAAAGGAAAAGGGTTTTTGTTGTGTTGTTGTTGTTGCTGTTTTTGAGACAAGGGTCTTGCTCTGTCATCATCCAGGCTGGAGTGCAGTGGTGCAGTCTCAGCTCACTGCAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGCAGCTAGGACTACAGGTGTGTGCCACCATGCCTGGCTAATTTTTGTATTTTTTAGTGGAAATGGGGTTTTGCCATGTTGCCCAGGCTCGTCTTGAACTCCTGACCTCAAGTGATCCACTCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCTATTGTCCCCAGCCAAAAGGAAAAGTTTTACTGTAGTAACCCTTCCGGACTAGGGACCTCGGGCCTCAGCCTCAGGCTACCTAGGTGCTTTAGAAAGGAGGCCACCCAGGCCCATGACTACTCCTTGCCACAGGGAGCCCTGCACACAGATGTGCTAAGCTCTCGCTGCCAGCCAGAGGGAGGAGGGTCTGAGCCAGTCAGAAGGAGATGGGCCCCAGAGAGTAAGAAAGGGGGAGGAGGACCCAAGCTGATCCAAAAGGTGGGTCTAAGCAGTCAAGTGGAGGAGGGTTCCAATCTGATGGCGGAGGGCCCAAGCTCAGCCTAACGAGGAGGCCAGGCCCACCAAGGGGCCCCTGGAGGACTTGTTTCCCTTGTCCCTTGTGGTTTTTTGCATTTCCTGTTCCCTTGCTGCTCATTGCGGAAGTTCCTCTTCTTACCCTGCACCCAGAGCCTCGCCAGAGAAGACAAGGGCAGAAAGCACCATGAGTGGGGGCCCAATGGGAGGAAGGCCCGGGGGCCGAGGAGCACCAGCGGTTCAGCAGAACATACCCTCCACCCTCCTCCAGGACCACGAGAACCAGCGACTCTTTGAGATGCTTGGACGAAAATGCTTGGTGAGCTGGGGATCTCCTGCCCCCGCCCCGTCCCCACCGTTTCTTCCTCTTCCTCTCCTCCTTCTCTCTCTTCCCCTCCTCCCGCTCCTCCTTTCCCTCTCCATCATCTCCTCTCCTAGAATTTCCCGTCATAATCCACCCTTCCCAGGAAGATCTCAATGTCTACTTGCCTTCCCTCTGGCTGCAGCTCTTCCTTTGGGCCCATGACTGTCATGAGGCAGGAAGGACCAGGTCTGGCTCCAAGACCTTGTGGCTACCCCTGACCAGACTCCACTGACCCCTGCTTTCCTCTCCCAGACGCTGGCCACTGCAGTTGTTCAGCTGTACCTGGCGCTGCCCCCTGGAGCTGAGCACTGGACCAAGGAGCATTGTGGGGCTGTGTGCTTCGTGAAGGATAACCCCCAGAAGTCCTACTTCATCCGCCTTTACGGCCTTCAGGTGACCCCCCCACCCCCGACTGGACTTGCAAGCCAGTTCTCAACCCGCAAACCCAGATCTGTGTCCATATGTGTCCATAGCTTCAAGACCTCAGACCTGATCAGTGAATCCCTGAGCCCCAGAACCAAAGACTCATCCAGATGGCAAACTCTGACTTGCCTTTCTAAGTCTGCAATGACTGGCCCCAGTCTCCGTATCAAGATCTCTAAAGCCCCCAGTATTAGTCTGCTGCCTAAGCCTAATCTTTTCCACAAATTCCAATAAATGAGCACTGTATTTGTACCTGAACCTCAAATCTATTCTAAACTCAACATTTTGCATCCCAGGAATCTCTCATCAAAACTCCTGAACCCCAGATGTTTGCCAAGCTCCTAAGTCATAAATCTGTTCAACAAACCCCAAAGTTGAATATTCCATTGATCCTTGAACTCCAAATCTGTCCTTCTAAATCCACAGCACAGACCCCAGAGTTCCCATATTAAAATTCCTGAACACTCAAATACCGAGGTAGTTCTTAAGCAAAAAGTCTTTTCCACAATCCCCTGACCTGAACTTTCTAGGTTTAAGCCCCAAATTCATCCTTTTAAACCCATAAAGATGGACCCAGCATAACTTCCAGATCCCAAGGCTATCAAATATCCACCAAACTCCTAAACCATAACTCTCTCCACAAACCCCAAATTGCACTTACTTTAGCTGGACTCCCCGCGAAACTCCCAAGTCTATGTGTCTGAACTTCAAATCTCAACTCCAACCCCCAAATACTAGAATCCTACCTGTCATGAATTGGGGCTGGGGTGGTGGGGGAGGGCATGGATTGAATCTGTGAATGAGCCTCAACTTCCTAAGACTAGAGTCCTAAATTATGAAATTCAAGCCCCCAAGTCCCAGATCTAGGGCCCCAAACCCCAAATCCAAACCTCTCACAAAAGTGTATGGCTCCCAGACTATACCCCACAATCCACACCCTTAGACACCAACTCTCTGGTGCTGAGCTGAAAATCTCCAAACCAGACTATGAGGCTCCCAAATCCAGACACCCTGCTCCCTGCCCAGCTAACAAAAGCCTGCCACCCCCGGCGTGCCTCAGTGCCACTGTGCCTCCCACCCTACACCTCTCCAGGCTGGTCGGCTGCTCTGGGAACAGGAGCTGTACTCACAGCTTGTCTACTCCACCCCCACCCCCTTCTTCCACACCTTCGCTGGAGATGTAAGTGATCAACCAGCCCTCGGGCCTCACTTGGGGTGTGGAGAGGAGATGGGAAAGTTGCGGGGGACCTGGGAGGCGGCTGACCCCAAGGTATGTGCAGGACTGCCAAGCGGGGCTGAACTTTGCAGACGAGGACGAGGCCCAGGCCTTCCGGGCCCTCGTGCAGGAGAAGATACAAAAAAGGAATCAGAGGCAAAGTGGAGGTGAGGAGGCCACAGGGGAGGAAAGGAAGTTGGGCAGAGGTGAGTGCAAGCCTGGGGAACTAGAAAAGTCCCCTCTCATGGTCCTGGCTCCCAATCCATCTATCCACAGACAGACGCCAGCTACCCCCACCACCAACACCAGCCAATGAAGGTGAGTCCTCTAGTGCAAGTAGGGGTAATAAGGGGCTAGCCCAGGAACCTGTGGCAGGGCTGTGATAACTCTCTACACATTCCATCTTCCCAGAGAGAAGAGGAGGGCTCCCACCCCTGCCCCTGCATCCAGGTGGAGACCAAGGAGGTGCGTGCTGATTCTTCCCTGTGTCTCTGGATGGATGGGTAAGAGTGGATGGAGGAATGAGGAGTTGGATGGGTGCGTAAGTGGGTGAATGGATAGGTAGATTGATAGGTATGTGGATGGACGAGCAGGTGCATGGATGTGTGGACTGATGGATGGGTGGATGGATTGGCGGTAGATGGCTGAGTAGAGGGATGAATTGATGGGAGGATGAAAGTCTAAGTAGATAGATGCATAGGTGAATGGGTATGTGGATAAATGAATGAAAAGGTAGATGGATGACTGAGTAAATTAATCAATGAGTGAATGAATGAACAGTGAATAAATGACTAAATGACAAGTTTCAGTCAGTGAAGAAAGCATGATTGAATGAATAAATGAGTAAATGAATATTTTAACAAATTCATTAGTCAATGAGCCAGTGAATGATAAAGCATGAGGGAATGAAAACATGAATGAATCAGTGAATGTATGAATGGTTTGTGGGATCCACCCACTTCTCCATAGACCCTACTTGAACCCTTCACCCACTACCTCCATGACCATCCAACACACACACAGATTTCCCTCAAGGCTTCCGTTTCTTGCCCCTGTGCTTTGGTTGGTTGGTAAGTGGGTCAATGAGCCAACCACCCTATTTTCCCCACAGGCCCTCCAGTGGGTCCGCTCTCCCTGGGGCTGGCGACAGTGGACATCCAGAACCCTGACATCACGAGTTCACGATACCGTGGGCTCCCAGCACCTGGACCTAGCCCAGCTGATAAGAAACGCTCAGGGAAGAAGAAGATCAGCAAAGCTGATATTGGTGCACCCAGTGGATTCAAGTGAGAGCCACTCCCCAGTGGACCCACAGATTCCTGGGGGCAGAGGGGCACATGAACAAGTGGACAGCTGAGTGAATGGAAGGATGGGCAGATGGGCAGATGGCTGGGTGGCTGAGTGGGTAAATGGGTGGTTGGATAGGTAGGTGCAGGGCTGGGTCTAGGGAGAGGTAAATAAGGCACCAAGGGTACAAAATTTAAGGAGGCACTCACTCTCAGAGGCATGCAACTGTAATTCCTGACTCTCAGAGTGAGTGACTCACTTAAATTTTGCACCCTAGGCACCTTACTTGCCTCACCCTGGGCCCACTCTGGGTGGGCTGTTAGGAGAGCAGGTGGGTGGGCAGGTGAACAAATGGATAGATAGATGAGGTAGATGATGGATGAGAAGGGCTGGTGGGTAGGTGGGTGAGTGGATGGGTGGATGGATGGATAAATGAATGGATGAATGAATGGGTTGAAGAATGAATGGATAAGTGGTTGGATGGACAAGTTTATGGGTGGATGGGTTGATGGGAGGTGCGTGGATAGATAGATGGGTGAGTGGATAGGTGTGTGGACAGATTGATATGCAGGCTGATTGGCTCACAGACAAGGTGGATGGGGATGGACAGGTGGACAGATACGTGGATGAATGGACAGTTCAATGGATAAGTGAACAGAAGTGTGTGGTTGCATGGGTAGAAAAATGAGTGGATGGATAGATGGAAAGGTGGGCACATGGGTAGGTGGATGGGTGGATGGACAAGTGTGTGTGAGGACAGACTGGTGGACAAATGGGTGAACAGACATATGTGGGCAGATAGTTGCAGAGACAGATGTATGGACAGATCAGTAGTCCAACAGATGAATGTGAATGAATAGGTGGACAAATGCATGGGATAGATGGGGAAAGAGGGATGGGTGGATGGATCAGCACCACAAACTATGGAGCCCTTCTAATTCCATAACTCCTGCCTATACTCATTCACTCATTCAGTCTCATTCATTAATTCTGGCCCCTCAGAGTCTCTTTGGGCAGGAGAGGGCAAGAGGGTTTCACTATGAAGGGAGGGAAGGAAGGGCAGTGAGGATTCACTGGAGTCTCTTCA-TGAAGAGACTCCAGTGAATCCTCACTGCCCTTCCTTCCCTCCCTTCATAGTGAAACCCTCTTGCCCTCTCCTGCCCAAAGAGACTCTGAGGGGCCAGAATTAATGAATGAGACTGAATGAGTGAATGAGTATAGGCAGGAGTTATGGAATTAGAAGGGCTCCATAGTTTGTGGTGCTGATCCATCCACCCATCCCTCTTTCCCCATCTATCCCATGCATTTGTCCACCTATTCATTCACATTCATCTGTTGGACTACTGATCTGTCCATACATCTGTCTCTGCAACTATCTGCCCACATATGTCTGTTCACCCATTTGTCCACCAGTCTGTCCTCACACACACTTGTCCATCCACCCATCCACCTACCCATGTGCCCACCTTTCCATCTATCCATCCACTCATTTTTCTACCCATGCAACCACACACTTCTGTTCACTTATCCATTGAACTGTCCATTCATCCACGTATCTGTCCACCTGTCCATCCCCATCCACCTTGTCTGTGAGCCAATCAGCCTGCATATCAATCTGTCCACACACCTATCCACTCACCCATCTATCTATCCACGCACCTCCCATCAACCCATCCACCCATAAACTTGTCCATCCAACCACTTATCCATTCATTCTTCAACCCATTCATTCATCCATTCATTTATCCATCCATCCACCCATCCACTCACCCACCTACCCACCAGCCCTTCTCATCCATCATCTACCTCATCTATCTATCCATTTGTTCACCTGCCCACCCACCTGCTCTCCTAACAGCCCACCCAGAGTGGGCCCAGGGTGAGGCAAGTAAGGTGCCTAGGGTGCAAAATTTAAGTGAGTCACTCACTCTGAGAGTCAGGAATTACAGTTGCATGCCTCTGAGAGTGAGTGCCTCCTTAAATTTTGTACCCTTGGTGCCTTATTTACCTCTCCCTAGACCCAGCCCTGCACCTACCTATCCAACCACCCATTTACCCACTCAGCCACCCAGCCATCTGCCCATCTGCCCATCCTTCCATTCACTCAGCTGTCCACTTGTTCATGTGCCCCTCTGCCCCCAGGAATCTGTGGGTCCACTGGGGAGTGGCTCTCACTTGAATCCACTGGGTGCACCAATATCAGCTTTGCTGATCTTCTTCTTCCCTGAGCGTTTCTTATCAGCTGGGCTAGGTCCAGGTGCTGGGAGCCCACGGTATCGTGAACTCGTGATGTCAGGGTTCTGGATGTCCACTGTCGCCAGCCCCAGGGAGAGCGGACCCACTGGAGGGCCTGTGGGGAAAATAGGGTGGTTGGCTCATTGACCCACTTACCAACCAACCAAAGCACAGGGGCAAGAAACGGAAGCCTTGAGGGAAATCTGTGTGTGTGTTGGATGGTCATGGAGGTAGTGGGTGAAGGGTTCAAGTAGGGTCTATGGAGAAGTGGGTGGATCCCACAAACCATTCATACATTCACTGATTCATTCATGTTTTCATTCCCTCATGCTTTATCATTCACTGGCTCATTGACTAATGAATTTGTTAAAATATTCATTTACTCATTTATTCATTCAATCATGCTTTCTTCACTGACTGAAACTTGTCATTTAGTCATTTATTCACTGTTCATTCATTCACTCATTGATTAATTTACTCAGTCATCCATCTACCTTTTCATTCATTTATCCACATACCCATTCACCTATGCATCTATCTACTTAGACTTTCATCCTCCCATCAATTCATCCCTCTACTCAGCCATCTACCGCCAATCCATCCACCCATCCATCAGTCCACACATCCATGCACCTGCTCGTCCATCCACATACCTATCAATCTACCTATCCATTCACCCACTTACGCACCCATCCAACTCCTCATTCCTCCATCCACTCTTACCCATCCATCCAGAGACACAGGGAAGAATCAGCACGCACCTCCTTGGTCTCCACCTGGATGCAGGGGCAGGGGTGGGAGCCCTCCTCTTCTCTCTGGGAAGATGGAATGTGTAGAGAGTTATCACAGCCCTGCCACAGGTTCCTGGGCTAGCCCCTTATTACCCCTACTTGCACTAGAGGACTCACCTTCATTGGCTGGTGTTGGTGGTGGGGGTAGCTGGCGTCTGTCTGTGGATAGATGGATTGGGAGCCAGGACCATGAGAGGGGACTTTTCTAGTTCCCCAGGCTTGCACTCACCTCTGCCCAACTTCCTTTCCTCCCCTGTGGCCTCCTCACCTCCACTTTGCCTCTGATTCCTTTTTTGTATCTTCTCCTGCACGAGGGCCCGGAAGGCCTGGGCCTCGTCCTCGTCTGCAAAGTTCAGCCCCGCTTGGCAGTCCTGCACATACCTTGGGGTCAGCCGCCTCCCAGGTCCCCCGCAACTTTCCCATCTCCTCTCCACACCCCAAGTGAGGCCCGAGGGCTGGTTGATCACTTACATCTCCAGCGAAGGTGTGGAAGAAGGGGGTGGGGGTGGAGTAGACAAGCTGTGAGTACAGCTCCTGTTCCCAGAGCAGCCGACCAGCCTGGAGAGGTGTAGGGTGGGAGGCACAGTGGCACTGAGGCACGCCGGGGGTGGCAGGCTTTTGTTAGCTGGGCAGGGAGCAGGGTGTCTGGATTTGGGAGCCTCATAGTCTGGTTTGGAGATTTTCAGCTCAGCACCAGAGAGTTGGTGTCTAAGGGTGTGGATTGTGGGGTATAGTCTGGGAGCCATACACTTTTGTGAGAGGTTTGGATTTGGGGTTTGGGGCCCTAGATCTGGGACTTGGGGGCTTGAATTTCATAATTTAGGACTCTAGTCTTAGGAAGTTGAGGCTCATTCACAGATTCAATCCATGCCCTCCCCCACCACCCCAGCCCCAATTCATGACAGGTAGGATTCTAGTATTTGGGGGTTGGAGTTGAGATTTGAAGTTCAGACACATAGACTTGGGAGTTTCGCGGGGAGTCCAGCTAAAGTAAGTGCAATTTGGGGTTTGTGGAGAGAGTTATGGTTTAGGAGTTTGGTGGATATTTGATAGCCTTGGGATCTGGAAGTTATGCTGGGTCCATCTTTATGGGTTTAAAAGGATGAATTTGGGGCTTAAACCTAGAAAGTTCAGGTCAGGGGATTGTGGAAAAGACTTTTTGCTTAAGAACTACCTCGGTATTTGAGTGTTCAGGAATTTTAATATGGGAACTCTGGGGTCTGTGCTGTGGATTTAGAAGGACAGATTTGGAGTTCAAGGATCAATGGAATATTCAACTTTGGGGTTTGTTGAACAGATTTATGACTTAGGAGCTTGGCAAACATCTGGGGTTCAGGAGTTTTGATGAGAGATTCCTGGGATGCAAAATGTTGAGTTTAGAATAGATTTGAGGTTCAGGTACAAATACAGTGCTCATTTATTGGAATTTGTGGAAAAGATTAGGCTTAGGCAGCAGACTAATACTGGGGGCTTTAGAGATCTTGATACGGAGACTGGGGCCAGTCATTGCAGACTTAGAAAGGCAAGTCAGAGTTTGCCATCTGGATGAGTCTTTGGTTCTGGGGCTCAGGGATTCACTGATCAGGTCTGAGGTCTTGAAGCTATGGACACATATGGACACAGATCTGGGTTTGCGGGTTGAGAACTGGCTTGCAAGTCCAGTCGGGGGTGGGGGGGTCACCTGAAGGCCGTAAAGGCGGATGAAGTAGGACTTCTGGGGGTTATCCTTCACGAAGCACACAGCCCCACAATGCTCCTTGGTCCAGTGCTCAGCTCCAGGGGGCAGCGCCAGGTACAGCTGAACAACTGCAGTGGCCAGCGTCTGGGAGAGGAAAGCAGGGGTCAGTGGAGTCTGGTCAGGGGTAGCCACAAGGTCTTGGAGCCAGACCTGGTCCTTCCTGCCTCATGACAGTCATGGGCCCAAAGGAAGAGCTGCAGCCAGAGGGAAGGCAAGTAGACATTGAGATCTTCCTGGGAAGGGTGGATTATGACGGGAAATTCTAGGAGAGGAGATGATGGAGAGGGAAAGGAGGAGCGGGAGGAGGGGAAGAGAGAGAAGGAGGAGAGGAAGAGGAAGAAACGGTGGGGACGGGGCGGGGGCAGGAGATCCCCAGCTCACCAAGCATTTTCGTCCAAGCATCTCAAAGAGTCGCTGGTTCTCGTGGTCCTGGAGGAGGGTGGAGGGTATGTTCTGCTGAACCGCTGGTGCTCCTCGGCCCCCGGGCCTTCCTCCCATTGGGCCCCCACTCATGGTGCTTTCTGCCCTTGTCTTCTCTGGCGAGGCTCTGGGTGCAGGGTAAGAAGAGGAACTTCCGCAATGAGCAGCAAGGGAACAGGAAATGCAAAAAACCACAAGGGACAAGGGAAACAAGTCCTCCAGGGGCCCCTTGGTGGGCCTGGCCTCCTCGTTAGGCTGAGCTTGGGCCCTCCGCCATCAGATTGGAACCCTCCTCCACTTGACTGCTTAGACCCACCTTTTGGATCAGCTTGGGTCCTCCTCCCCCTTTCTTACTCTCTGGGGCCCATCTCCTTCTGACTGGCTCAGACCCTCCTCCCTCTGGCTGGCAGCGAGAGCTTAGCACATCTGTGTGCAGGGCTCCCTGTGGCAAGGAGTAGTCATGGGCCTGGGTGGCCTCCTTTCTAAAGCACCTAGGTAGCCTGAGGCTGAGGCCCGAGGTCCCTAGTCCGGAAGGGTTACTACAGTAAAACTTTTCCTTTTGGCTGGGGACAATAGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGACGAGTGGATCACTTGAGGTCAGGAGTTCAAGACGAGCCTGGGCAACATGGCAAAACCCCATTTCCACTAAAAAATACAAAAATTAGCCAGGCATGGTGGCACACACCTGTAGTCCTAGCTGCTCAGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCTGAGACTGCACCACTGCACTCCAGCCTGGATGATGACAGAGCAAGACCCTTGTCTCAAAAACAGCAACAACAACAACACAACAAAAACCCTTTTCCTTTTAATTACAGAGCGAGCCCCTGTGATCCACGCCTATCGTGAGTGCTTAGACACTGCCAATGACGCATATGCCTCTGGTCCACTTCCCCATCCCTTACCCTTGCCTCCCCGCAGCTCCCAAATTACTTTCTGCTTGTCATACTTTTTTTTTTCTTTTTTTTTTTGAGATGGAGTCTCACTCTGTCGCCAGGCTGGAGTGCGGTGGCACGATCTCGGCTCACTGCAACCTTTGCCTCCCGGGTTCAAGTGACTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACACGCCACCACGCCCAGCTAATTTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCCAGGATGGTCTCGATTTCTCGACCTCGTGATCCACCTGCCTCGGCCTCCCAAAGTATTAGAATTACAGGCGTGAGCCACCGTGCCCAGCCCATCCCTTTTTTAAAGAAAGGAACTTTATATCATATATGAATGCCTGAACAACATCTTGTTTAGTTTTCATTGCACTTGAAGTTTGTAAAAGCACATAATCTTCAAAGGCTTGCTTTCTCCCCACTGGACATCCTAGTTTTATCTTAACACTCACATAGCACTTAACGTGTGTGCCAGTCACTGTTCTGACCCCTTTGCCCGGAGTGCGAGCCAGGCAGGCCAGGTGTGAGTGCATGGTCTCGTCCCTCCACGCCTTCACTCTTGGCTGTTGCTGTGATTCCTGTTTGCCTATAGTGGTAGCTGTTCATTTATTTCCACTGCCATACAGCATTCCATGGTGTGCATGTGCAGCCTGGGTGTCCATATTCTCCTGTAACAGCCCTTTGGGCTGCTTCTGGTTCTTGCTGTTGGGAGCAACACTGCAGTGTTCACTCCCGCACACATCTCCTGGTCCACATAGGCATGCAGACTCTCAGACGGGAATCTGAGGGCTGTAGGGTTTGCATGTCTCTAACTTCTCCAGATGATGCCAGACTATTTCCACAAGTGAATGCTAGCTCAGTCCCCGGCCTCCCCAGGCCTCAGTTTCCCCATGTATGAGGTAGGCCATTTGGAGACTTGAAGCTCTCAGATACAGGAACAGCAGTTTGGGGGAGCTGAGCAGGTCTGGGGTGTGACTGACATTCCCAGGTACCTGAAGGAGGAACGGCACATCTCCAGTTGGGACCTGCAGTCCTTCCTGGAAACTTCCATGGCTTCCCACACGTGCAGGTTCAAAGCCTCTCTCCTGAACCTAGGTTCAGAACCCCTTCTGCAGTGGCAGTTCCAACCTCCCTCCCGTGTCCCCACTCACAGCTAAGCTTCGGGCCTGGAGCACCTCCAACCTGCTG Wiskott-Aldrich syndrome Pathogenic (Feb 20, 2015)638576
X-48683512-T-C Benign (Apr 25, 2019)1265197
X-48683814-ACCCAGAGCCTCGCCAGAGAAGACAAGGGCAGAAAGCACCATGAGTGGGGGCCCAATGGGAGGAAGGCCCGGGGGCCGAGGAGCACCAGCGGTTCAGCAGAACATACCCTCCACCCTCCTCCAGGACCACGAGAACCAGCGACTCTTTGAGATGCTTGGACGAAAATGCTTGGTGAGCTGGGGATCTCCTGCCCCCGCCCCGTCC-A Thrombocytopenia 1;Wiskott-Aldrich syndrome;X-linked severe congenital neutropenia Pathogenic (Dec 11, 2018)663734
X-48683854-A-T Wiskott-Aldrich syndrome Pathogenic (Apr 01, 2006)11120
X-48683859-T-C X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Benign (Apr 28, 2023)2925814
X-48683859-TG-T Wiskott-Aldrich syndrome • Thrombocytopenia 1;X-linked severe congenital neutropenia;Wiskott-Aldrich syndrome Pathogenic (May 24, 2019)11132
X-48683869-A-G not specified • X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Conflicting classifications of pathogenicity (Nov 04, 2023)1685211
X-48683870-TGGGAGGAAGGCCCGGGGGCCGAG-T Thrombocytopenia 1;Wiskott-Aldrich syndrome;X-linked severe congenital neutropenia Pathogenic (Sep 16, 2022)2030805
X-48683872-G-T Pathogenic (Aug 07, 2015)419588
X-48683874-AG-A Pathogenic (Aug 04, 2020)817607
X-48683881-C-T X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Uncertain significance (Oct 09, 2023)2930603
X-48683883-C-A X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Likely benign (Jan 08, 2024)2928232
X-48683883-C-G X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Likely benign (Aug 24, 2022)2026804
X-48683883-C-T X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Likely benign (Jan 21, 2024)2923687
X-48683883-C-CG Wiskott-Aldrich syndrome • X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Pathogenic (Jun 22, 2022)843981
X-48683890-C-T Wiskott-Aldrich syndrome • Wiskott-Aldrich syndrome;Thrombocytopenia 1;X-linked severe congenital neutropenia Pathogenic (Aug 01, 2024)36911
X-48683891-G-A Thrombocytopenia 1;Wiskott-Aldrich syndrome;X-linked severe congenital neutropenia Conflicting classifications of pathogenicity (Jun 11, 2023)2660462
X-48683892-AG-CC not specified • X-linked severe congenital neutropenia;Wiskott-Aldrich syndrome;Thrombocytopenia 1 Uncertain significance (Apr 29, 2022)135408
X-48683899-C-G X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Uncertain significance (Sep 19, 2022)1956732
X-48683902-G-T X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Uncertain significance (Aug 24, 2021)566587
X-48683903-C-T X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Likely benign (Jan 06, 2023)2929244
X-48683904-G-A X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Likely benign (Aug 06, 2023)2922474
X-48683904-G-C X-linked severe congenital neutropenia;Thrombocytopenia 1;Wiskott-Aldrich syndrome Likely benign (Oct 06, 2023)2926599
X-48683905-G-A Thrombocytopenia 1;Wiskott-Aldrich syndrome;X-linked severe congenital neutropenia Uncertain significance (Sep 24, 2021)1447769
X-48683907-T-G Likely benign (Oct 01, 2023)2660463

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
WASprotein_codingprotein_codingENST00000376701 1214834
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9990.00099400000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.981292090.6160.00001743153
Missense in Polyphen2271.0190.309781016
Synonymous0.6178087.30.9160.000007711103
Loss of Function4.15020.00.000.00000176263

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Effector protein for Rho-type GTPases that regulates actin filament reorganization via its interaction with the Arp2/3 complex (PubMed:12235133, PubMed:12769847, PubMed:16275905). Important for efficient actin polymerization (PubMed:8625410, PubMed:12235133, PubMed:16275905). Possible regulator of lymphocyte and platelet function (PubMed:9405671). Mediates actin filament reorganization and the formation of actin pedestals upon infection by pathogenic bacteria (PubMed:18650809). In addition to its role in the cytoplasmic cytoskeleton, also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA (PubMed:20574068). Promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs) (PubMed:29925947). {ECO:0000269|PubMed:12235133, ECO:0000269|PubMed:12769847, ECO:0000269|PubMed:16275905, ECO:0000269|PubMed:18650809, ECO:0000269|PubMed:20574068, ECO:0000269|PubMed:29925947, ECO:0000269|PubMed:8625410, ECO:0000269|PubMed:9405671}.;
Disease
DISEASE: Wiskott-Aldrich syndrome (WAS) [MIM:301000]: An X-linked recessive immunodeficiency characterized by eczema, thrombocytopenia, recurrent infections, and bloody diarrhea. Death usually occurs before age 10. {ECO:0000269|PubMed:10447259, ECO:0000269|PubMed:11793485, ECO:0000269|PubMed:20574068, ECO:0000269|PubMed:7753869, ECO:0000269|PubMed:8528198, ECO:0000269|PubMed:8528199, ECO:0000269|PubMed:8682510, ECO:0000269|PubMed:9098856, ECO:0000269|PubMed:9126958, ECO:0000269|PubMed:9445409, ECO:0000269|PubMed:9683546, ECO:0000269|PubMed:9713366}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Thrombocytopenia 1 (THC1) [MIM:313900]: Thrombocytopenia is defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. {ECO:0000269|PubMed:10447259, ECO:0000269|PubMed:11167787, ECO:0000269|PubMed:11877312, ECO:0000269|PubMed:7795648, ECO:0000269|PubMed:8528199}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Neutropenia, severe congenital, X-linked (XLN) [MIM:300299]: A disorder of hematopoiesis characterized by maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. {ECO:0000269|PubMed:11242115}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Fc gamma R-mediated phagocytosis - Homo sapiens (human);Salmonella infection - Homo sapiens (human);Choline metabolism in cancer - Homo sapiens (human);Adherens junction - Homo sapiens (human);Endocytosis - Homo sapiens (human);Tight junction - Homo sapiens (human);Chemokine signaling pathway - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Bacterial invasion of epithelial cells - Homo sapiens (human);Shigellosis - Homo sapiens (human);Pathogenic Escherichia coli infection - Homo sapiens (human);Pathogenic Escherichia coli infection;Human Complement System;Chemokine signaling pathway;Regulation of Actin Cytoskeleton;G13 Signaling Pathway;T-Cell antigen Receptor (TCR) Signaling Pathway;Signal Transduction;Generation of second messenger molecules;TCR signaling;Fcgamma receptor (FCGR) dependent phagocytosis;TCR;Innate Immune System;Immune System;RHO GTPases Activate WASPs and WAVEs;Adaptive Immune System;KitReceptor;RHO GTPase Effectors;Signaling by Rho GTPases;Regulation of actin dynamics for phagocytic cup formation;TCR signaling in naïve CD4+ T cells (Consensus)

Recessive Scores

pRec
0.559

Intolerance Scores

loftool
rvis_EVS
0.51
rvis_percentile_EVS
80.01

Haploinsufficiency Scores

pHI
0.845
hipred
Y
hipred_score
0.775
ghis
0.524

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.539

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Was
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; endocrine/exocrine gland phenotype; hematopoietic system phenotype; digestive/alimentary phenotype; renal/urinary system phenotype; skeleton phenotype; immune system phenotype;

Gene ontology

Biological process
actin cortical patch assembly;regulation of T cell antigen processing and presentation;endocytosis;defense response;immune response;Rho protein signal transduction;blood coagulation;regulation of actin polymerization or depolymerization;actin polymerization or depolymerization;epidermis development;regulation of lamellipodium assembly;endosomal transport;actin filament polymerization;actin filament-based movement;Cdc42 protein signal transduction;Fc-gamma receptor signaling pathway involved in phagocytosis;T cell activation;positive regulation of transcription by RNA polymerase II;regulation of catalytic activity;T cell receptor signaling pathway;positive regulation of actin nucleation;regulation of stress fiber assembly;negative regulation of stress fiber assembly;actin cortical patch localization;protein-containing complex assembly;cellular response to interferon-gamma;positive regulation of double-strand break repair via homologous recombination;negative regulation of cell motility;positive regulation of Arp2/3 complex-mediated actin nucleation;regulation of double-strand break repair via nonhomologous end joining
Cellular component
nucleus;cytosol;actin filament;cell-cell junction;vesicle membrane;actin cytoskeleton;actin cortical patch;site of double-strand break;phagocytic vesicle;extracellular exosome
Molecular function
protein binding;SH3 domain binding;protein kinase binding;GTPase regulator activity;small GTPase binding;identical protein binding;phospholipase binding;Rac GTPase binding;actin filament binding